Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.
Rajamani BM, Benjamin ESB, Abraham A, Ganesan S, Lakshmi KM, Anandan S, Karathedath S, Varatharajan S, Mohanan E, Janet NB, Srivastava VM, Ramachandran Velayudhan S, Kulkarni UP, Devasia AJ, Fouzia NA, Korula A, George B, Srivastava A, Mathews V, Balasubramanian P.
Rajamani BM, et al. Among authors: srivastava vm, srivastava a.
Sci Rep. 2020 Nov 26;10(1):20640. doi: 10.1038/s41598-020-77140-9.
Sci Rep. 2020.
PMID: 33244077
Free PMC article.